614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Poster I

Dynamic changes in myeloid derived suppressor cells subsets in pediatric B cell acute lymphoblastic leukemia Correlation with measurable residual disease status

Exploring the immunodynamic landscape of blinatumomab therapy in pediatric BCP ALL through full spectrum flow cytometry

Hemodilution assessment for high sensitivity flow cytometric measurable residual disease evaluation in pediatric B cell acute lymphoblastic leukemia

Single cell transcriptomics of matched cerebrospinal fluid and bone marrow patient samples highlights the role for CXCR4 in acute lymphoblastic leukemia CNS disease

Characterization of cerebrospinal fluid pleocytosis and cell subsets during blinatumomab therapy for pediatric B ALL A real life study from China

Protein expression signatures reveal age specific risk patterns in B ALL

Siglec 15 dependent alteration of the leukemia immune microenvironment

Utility of peripheral blood cell free DNA in detecting minimal residual disease in patients receiving CAR T cell therapy for B acute lymphoblastic leukemia B ALL

PROK1 locus variant identified as a genetic determinant of anthracycline related cardiomyopathy in long term childhood acute leukemia survivors

Long read profiling of structural variants reveals mechanisms of chemo resistance and prognostic heterogeneity in acute lymphoblastic leukemia

Low intensity cytoreduction with low dose cytarabine prior to blinatumomab for pediatric and AYA R R ALL integrated with multi omics analysis to discover predictive biomarkers Initial results from JPLSG ALL R19 blin